Development of HeartPrint Bioink

HeartPrint Bioink 的开发

• 批准号: 571266-2022
• 负责人: Willerth, Stephanie
• 金额: $ 1.46万
• 依托单位: University of Victoria
• 依托单位国家: 加拿大
• 项目类别: Idea to Innovation
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=729119
• 关键词: Development; HeartPrint; Bioink

3D bioprinting enables to generation of human tissue models for screening potential drug targets in a more relevant fashion compared to animal models. Animal models fail to predict the toxicity of potential drug targets on cardiovascular system, including the heart. 40% of drugs that enter clinical trials fail as a result of unexpected cardiotoxicity. Thus, a huge market exists for a bioink capable of printing human cardiac tissues that can be used to screen potential drugs for this issue. This project will upon our team's expertise in producing TissuePrint and BrainPrint to perform the research and development necessary to generate such a bioink, which we have termed "HeartPrint". HeartPrint bioink fills this important market gap and this project will further enable research and development here in Canada. This Lab to Market project will be conducted by Milena Perez - an award winning biomedical engineer at the University of Victoria - who has already published three well received, peer reviewed journal articles about using 3D bioprinting to produce stem cell-derived tissues. This project will be conducted under the guidance of Dr. Willerth - an internationally recognized expert in 3D printing and tissue engineering.

与动物模型相比，3D Bioprinting可以以更相关的方式生成人体组织模型，以筛选潜在的药物靶标。动物模型无法预测包括心脏在内的心血管系统的潜在药物靶标的毒性。由于意外的心脏毒性，进入临床试验的药物中有40％失败。因此，对于能够打印人类心脏组织的生物互联的巨大市场，可用于筛查该问题的潜在药物。该项目将依靠我们团队在生产组织和脑印方面的专业知识，以执行产生这种生物焦所必需的研究和开发，而我们称其为“心脏”。 Heartprint Bioink填补了这一重要的市场差距，该项目将进一步使加拿大的研发能够实现。该实验室到市场项目将由维多利亚大学屡获殊荣的生物医学工程师米娜·佩雷斯（Milena Perez）进行。该项目将在Willerth博士的指导下进行，这是国际公认的3D印刷和组织工程专家。